Rhumbline Advisers Has $120,000 Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Rhumbline Advisers raised its holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 14.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,135 shares of the company’s stock after acquiring an additional 7,290 shares during the period. Rhumbline Advisers owned about 0.10% of Black Diamond Therapeutics worth $120,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Walleye Capital LLC bought a new position in Black Diamond Therapeutics in the third quarter valued at about $49,000. Intech Investment Management LLC bought a new position in Black Diamond Therapeutics in the third quarter valued at about $56,000. SG Americas Securities LLC bought a new position in Black Diamond Therapeutics in the fourth quarter valued at about $42,000. MetLife Investment Management LLC grew its position in Black Diamond Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 22,286 shares of the company’s stock valued at $97,000 after acquiring an additional 12,557 shares during the last quarter. Finally, Barclays PLC grew its position in Black Diamond Therapeutics by 201.9% in the third quarter. Barclays PLC now owns 78,151 shares of the company’s stock valued at $339,000 after acquiring an additional 52,265 shares during the last quarter. Institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Price Performance

Shares of BDTX stock opened at $1.71 on Tuesday. The business’s 50 day simple moving average is $2.23 and its 200 day simple moving average is $3.13. Black Diamond Therapeutics, Inc. has a one year low of $1.59 and a one year high of $7.66. The stock has a market capitalization of $96.76 million, a PE ratio of -1.29 and a beta of 2.52.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03. As a group, research analysts expect that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current year.

Analyst Ratings Changes

BDTX has been the topic of several research reports. Wedbush restated an “outperform” rating and set a $11.00 price target (down from $16.00) on shares of Black Diamond Therapeutics in a report on Friday. Stifel Nicolaus reduced their price target on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Friday. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Black Diamond Therapeutics presently has a consensus rating of “Buy” and an average price target of $14.40.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.